QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ATAI

QT69Atai Beckley Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
4.06
-0.01-0.25%
OverviewShort InterestFilings
ATAIQT69Atai Beckley Inc.·NASDAQ
OverviewShort InterestFilings
4.06-0.25%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.00
Insider Own27.54%
Shs Outstand368.17M
Perf Week6.84%
Market Cap1.50BForward P/E-EPS next Y-0.44Insider Trans-Shs Float-Perf Month2.53%
Enterprise Value1.46BPEG0.01EPS next Q-0.12Inst Own-Short Float-Perf Quarter13.73%
Income-1078126402.00P/S429.60EPS this Y85.79%Inst Trans-Short Ratio-Perf Half Y-4.02%
Sales3.49MP/B4.64EPS next Y-3.29%ROA-250.46%Short Interest-Perf YTD-0.73%
Book/sh0.54P/C-EPS next 5Y-ROE-366.49%52W High6.75 -39.85%Perf Year82.88%
Cash/sh0.63P/FCF-EPS past 3/5Y-ROIC-53.11%52W Low2.00 103.00%Perf 3Y-
Dividend Est.-EV/EBITDA-2.20Sales past 3/5Y-Gross Margin82.02%Volatility5.05% 4.80%Perf 5Y-
Dividend TTM-EV/Sales417.81EPS Y/Y TTM40.86%Oper. Margin-3658.03%ATR (14)0.30Perf 10Y-
Dividend Ex-DateAug 27, 2018Quick Ratio10.02Sales Y/Y TTM-Profit Margin-19019.44%RSI (14)48.20Recom2.00
Dividend Gr. 3/5Y-Current Ratio10.02EPS Q/Q46.67%SMA20-3.47%Beta1.50Target Price12.00
Payout0.00%Debt/Eq0.01Sales Q/Q-50.00%SMA50-3.00%Rel Volume1.09Prev Close4.07
Employees99LT Debt/Eq0.01EarningsAug 13SMA200-5.31%Avg Volume6.09MPrice4.06
IPO DateJun 18, 2021Option/ShortYes / YesEPS/Sales Surpr.27.27% -Net Debt/EBITDA0.06Volume6,620,893Change-0.25%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-20-26ReiteratedCanaccord GenuityBuy$14 → $15
Mar-27-26InitiatedDeutsche BankBuy$12
Mar-06-26ReiteratedJefferies$5.00 → $10
Jan-20-26InitiatedGuggenheimBuy$11
Oct-22-25ReiteratedCanaccord GenuityBuy$14
Oct-13-25InitiatedNeedhamBuy$12
May-20-25ReiteratedJefferies$5.00
Apr-03-24ReiteratedMaxim Group$6.00
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue440
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A010
Gross Profit330
Selling, General and Administrative Excl. Other685048
Research and Development625355
Other Operating Expense100
Operating Income-127-100-103
Interest Expense013
Unusual Expense
———
Non-Operating Income (Expense)53655945
Net Income Before Taxes-664-660-151
Income Taxes00-1
Consolidated Net Income-664-660-149
Net Income From Continuing Operations-664-660-150
Net Income-664-660-149
EPS (Recurring)-3.00-2.91-0.93
EPS (Basic, Before Extraordinaries)-3.00-2.91-0.93
EPS (Diluted)-3.00-2.91-0.93
EBITDA-663-658-147
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio230.40232.11—
Gross Margin75.0075.00—
Operating Margin-3,175.00-2,500.00—
Net Margin-16,600.00-16,500.00—
Shares Outstanding227227160
Market Capitalization922928—
Operating Lease Expense
———
Insider Trading Volume
$4.45$4.24$4.03$3.81$3.60● Close Price0.00M4.75M9.50M14.25M19.00MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Apeiron Investment Group Ltd.10% OwnerAug 14 '25Buy2.198,675,79919,000,00051,045,214Aug 18 12:00 AM
Apeiron Investment Group Ltd.10% OwnerMar 24 '25Buy1.401,800,0002,520,00042,369,415Mar 24 12:00 AM
Short Glenn FrankChief Scientific OfficerMar 21 '25Sale1.3513,16117,76742,333Mar 24 12:00 AM
Rao SrinivasSee RemarksMar 21 '25Sale1.3575,418101,814212,942Mar 24 12:00 AM
Kirpekar SahilChief Business OfficerMar 21 '25Sale1.3548,56365,560115,636Mar 24 12:00 AM
Craig Kevin JamesChief Medical OfficerMar 21 '25Sale1.3511,56315,6108,437Mar 24 12:00 AM
Johnson Anne NagengastChief Financial OfficerMar 21 '25Sale1.3533,54545,286140,045Mar 24 12:00 AM
Kirpekar SahilChief Business OfficerMar 14 '25Option Exercise0.00200,0000164,199Mar 19 12:00 AM
Johnson Anne NagengastChief Financial OfficerMar 14 '25Option Exercise0.00200,0000173,590Mar 19 12:00 AM
Short Glenn FrankChief Scientific OfficerMar 14 '25Option Exercise0.0065,000055,494Mar 19 12:00 AM
Craig Kevin JamesChief Medical OfficerMar 14 '25Option Exercise0.0040,000020,000Mar 19 12:00 AM
Rao SrinivasSee RemarksMar 14 '25Option Exercise0.00350,0000288,360Mar 19 12:00 AM
Apeiron Investment Group Ltd.10% OwnerFeb 14 '25Buy2.1010,835,71822,755,00840,555,215Feb 19 12:00 AM
Brand FlorianSee RemarksMay 16 '24Sale1.92151,303290,502328,697May 20 12:00 AM
Johnson Anne NagengastChief Financial OfficerApr 02 '24Sale1.8527,41050,70973,590Apr 04 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR